Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AndroMETa-CRC-064: An Open-Label, Randomized Global Dose Optimization Study Comparing Two Doses of Telisotuzumab Adizutecan (ABBV-400) Monotherapy in Subjects With Refractory Metastatic Colorectal Cancer Expressing c-Met Protein Level Above a Defined Cutoff

NCT06614192 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06614192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06614192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AndroMETa-CRC-064: An Open-Label, Randomized Global Dose Optimization Study Comparing Two Doses of Telisotuzumab Adizutecan (ABBV-400) Monotherapy in Subjects With Refractory Metastatic Colorectal Cancer Expressing c-Met Protein Level Above a Defined Cutoff
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 8, 2024
Completion date
August 31, 2027
Enrollment
74 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer